(Q36948436)

English

Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

scientific article published on January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature (English)

1 reference

Europe PubMed Central

17 August 2017

Alzheimer's disease

0 references

phosphorylation

0 references

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

mild cognitive impairment

1 reference

based on heuristic

inferred from title

cognitive dysfunction

1 reference

based on heuristic

inferred from title

author name string

Breno S O Diniz

1

1 reference

Europe PubMed Central

17 August 2017

Jony A Pinto Júnior

2

1 reference

Europe PubMed Central

17 August 2017

Orestes Vicente Forlenza

3

1 reference

Europe PubMed Central

17 August 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

17 August 2017

World Journal of Biological Psychiatry

1 reference

Europe PubMed Central

17 August 2017

9

1 reference

Europe PubMed Central

17 August 2017

172-182

1 reference

Europe PubMed Central

17 August 2017

3

1 reference

Europe PubMed Central

17 August 2017

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Natural history of mild cognitive impairment in older persons

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Beta-secretase as a target for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Mild cognitive impairment, amnestic type: an epidemiologic study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Tau protein and the neurofibrillary pathology of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

International quality control survey of neurochemical dementia diagnostics.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPECT in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Neuropathologic features of amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Intrathecal inflammation precedes development of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Conversion to dementia from mild cognitive disorder: the Cache County Study.

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Brain reserve and dementia: a systematic review

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Cerebrospinal fluid markers for prediction of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F15622970701535502

21 January 2018

Identifiers

10.1080/15622970701535502

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36948436&oldid=1664405277"